Evidence map›Paper›PMID 26051676›Full record

ArticleJournal of proteome research2015

Experimental Null Method to Guide the Development of Technical Procedures and to Control False-Positive Discovery in Quantitative Proteomics.

Xiaomeng Shen, Qiang Hu, Jun Li, Jianmin Wang, Jun Qu

Abstract read
In one paragraph

Article in Journal of proteome research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Species-Deconvolved Proteomics forJournal of proteome research · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Quantitative proteomic and phosphoproteomic profiling of ischemic myocardial stunning in swine.American journal of physiology. Heart and circulatory physiology · 2020
    Article
  9. Review
  10. IonStar enables high-precision, low-missing-data proteomics quantification in large biological cohorts.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaomeng Shen
Qiang HuDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute , Elm and Carlton Streets, Buffalo, New York 14263, United States.
Jun Li
Jianmin WangDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute , Elm and Carlton Streets, Buffalo, New York 14263, United States.
Jun Qu

Funding

Systems Biology of GlycosylationR01HL103411 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI NEELAMEGHAM, SRIRAM · 2011 to 2025
$7.1M
Synergistic Pharmacologicjntervention for Prevention of ROP (SPIPROP STUDY)U54HD071594 · NICHD · SUNY DOWNSTATE MEDICAL CENTER · PI BRUNKEN, WILLIAM J · 2011 to 2015
$3.6M
Multi-scale modeling of asymmetric cell divisionR01GM095990 · NIGMS · CORNELL UNIVERSITY · PI SHEN, XILING · 2011 to 2015
$1.5M
Robustness of the Intestinal Stem Cell NicheR01GM114254 · NIGMS · DUKE UNIVERSITY · PI SHEN, XILING · 2015 to 2017
$918k
Functional mapping of efferent gut neuroepithelial circuitsOT2OD023849 · OD · DUKE UNIVERSITY · PI SHEN, XILING · 2016 to 2016
$493k
Novel Stem Cell Therapy for Acute Myocardial Infarction in Diabetes MellitusR43HL132774 · NHLBI · TRANSTARGET, INC. · PI WANG, JIANMING · 2016 to 2016
$225k
NHLBI NIH HHS HL103411NHLBI NIH HHS R01 HL103411NHLBI NIH HHS R43 HL132774NICHD NIH HHS U54 HD071594NICHD NIH HHS U54HD071594NIGMS NIH HHS R01 GM095990NIGMS NIH HHS R01 GM114254NIH HHS OT2 OD023849
6 · The paper itself

Abstract

Comprehensive and accurate evaluation of data quality and false-positive biomarker discovery is critical to direct the method development/optimization for quantitative proteomics, which nonetheless remains challenging largely due to the high complexity and unique features of proteomic data. Here we describe an experimental null (EN) method to address this need. Because the method experimentally measures the null distribution (either technical or biological replicates) using the same proteomic samples, the same procedures and the same batch as the case-vs-contol experiment, it correctly reflects the collective effects of technical variability (e.g., variation/bias in sample preparation, LC-MS analysis, and data processing) and project-specific features (e.g., characteristics of the proteome and biological variation) on the performances of quantitative analysis. To show a proof of concept, we employed the EN method to assess the quantitative accuracy and precision and the ability to quantify subtle ratio changes between groups using different experimental and data-processing approaches and in various cellular and tissue proteomes. It was found that choices of quantitative features, sample size, experimental design, data-processing strategies, and quality of chromatographic separation can profoundly affect quantitative precision and accuracy of label-free quantification. The EN method was also demonstrated as a practical tool to determine the optimal experimental parameters and rational ratio cutoff for reliable protein quantification in specific proteomic experiments, for example, to identify the necessary number of technical/biological replicates per group that affords sufficient power for discovery. Furthermore, we assessed the ability of EN method to estimate levels of false-positives in the discovery of altered proteins, using two concocted sample sets mimicking proteomic profiling using technical and biological replicates, respectively, where the true-positives/negatives are known and span a wide concentration range. It was observed that the EN method correctly reflects the null distribution in a proteomic system and accurately measures false altered proteins discovery rate (FADR). In summary, the EN method provides a straightforward, practical, and accurate alternative to statistics-based approaches for the development and evaluation of proteomic experiments and can be universally adapted to various types of quantitative techniques.

Indexed as

ArtifactsAnimalsBiomarkersBrainBrain ChemistryChromatography, LiquidEscherichia coliGene Expression ProfilingGene Expression RegulationHumansLeukocytes, MononuclearLiverProteomeProteomicsRatsReference StandardsBiomarkersProteomeexperimental null (EN)false altered proteins discovery rate (FADR)ion-current-based quantificationquantitative proteomics

Identifiers

PMID26051676
PMCPMC5905339

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.